Detalles de la búsqueda
1.
Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.
Chem Res Toxicol
; 25(5): 1075-85, 2012 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-22390216
2.
Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA.
Neuro Endocrinol Lett
; 29(5): 728-32, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18987592
3.
Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
Toxicology
; 236(1-2): 50-60, 2007 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17482743
4.
Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
; 150(1): 13-23, 2006 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-16936898
5.
The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Cancer Res
; 64(22): 8374-80, 2004 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15548707
6.
Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
Chem Res Toxicol
; 16(1): 38-47, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12693029
7.
DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
Int J Cancer
; 107(6): 885-90, 2003 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-14601046
Resultados
1 -
7
de 7
1
Próxima >
>>